This systematic review summarizes the available published evidence on associations between patient survival and surrogate end points used in medical oncology trials and find the correlations to be generally low.
This cross-sectional analysis finds that significant departures from good clinical practice in clinical trials identified by the FDA are seldom reflected in the peer-reviewed literature, even when there is evidence of data fabrication or other forms of research misconduct.
This study found that few drug labels contained or referenced convincing evidence of clinical utility of biomarker testing, whereas many made recommendations based on biomarker test results. See also the Invited Commentary by Burke.
Lamontagne and colleagues describe the frequency, anatomical location, risk factors, management, and consequences of nonleg deep venous thromboses in a large cohort of medical-surgical critically ill adults. Maynard provides an Invited Commentary.
This survey study found that whereas physicians in Asian intensive care units often withheld but seldom withdrew life-sustaining treatments at the end of life, attitudes and practice varied widely across countries and regions.
This randomized clinical trial evaluates the use of high-dose sodium selenite, with or without use of a procalcitonin algorithm to guide therapy, and its association with mortality in patients with severe sepsis.
This clinical trial examines the effect of 3 different presentations of benefits and harms on patients’ intentions to accept low-value or potentially low-value screening services.
Results of this secondary analysis of the PREDIMED trial suggest a beneficial effect of a Mediterranean diet supplemented with extra-virgin olive oil in the primary prevention of breast cancer.